Innova Captab Ltd (INNOVACAP)
₹1,025.30
Mkt cap
₹5,867 Cr
P/E ratio
38.10
P/B
5.37
Div yield
0.20%
ROE
13.70%
ROCE
15.00%
EPS (TTM)
₹26.91
Book value
₹191
52W range
622–1,354
Sector
Healthcare
Price history
Previous close
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain. [1]
NSE INNOVACAPBSE 544067
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−24.25% from high₹1,025
₹622+64.84% from low₹1,354
Current
₹1,025.30
Prev close
₹1,051.10
Day
−2.45%
Price performance
1D
+0.36%
1W
+6.85%
1M
−17.02%
3M
+8.80%
6M
+44.82%
1Y
+31.11%
YTD
+41.39%
Financials
Revenue, profit & margin
P/E ratio
38.1×
INNOVACAP is 11% above the sector median of 34.4×
INNOVACAP38.1×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 233 | 283 | 302 | 263 | 294 | 318 | 316 | 315 | 352 | 380 | 450 | 448 | 471 | |
| Expenses | 202 | 242 | 258 | 225 | 252 | 268 | 270 | 267 | 299 | 329 | 381 | 383 | 398 | |
| Operating Profit | 31 | 40 | 45 | 38 | 42 | 50 | 47 | 48 | 52 | 52 | 69 | 65 | 73 | |
| OPM % | 13% | 14% | 15% | 14% | 14% | 16% | 15% | 15% | 15% | 14% | 15% | 15% | 16% | |
| Other Income | 1 | 3 | 2 | 6 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 | 2 | |
| Interest | 5 | 9 | 7 | 1 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 5 | 4 | |
| Depreciation | 3 | 5 | 5 | 3 | 5 | 5 | 5 | 10 | 11 | 11 | 11 | 11 | 12 | |
| Profit before tax | 25 | 30 | 35 | 40 | 39 | 47 | 46 | 39 | 43 | 39 | 56 | 51 | 59 | |
| Tax % | 28% | 24% | 29% | 27% | 25% | 25% | 25% | 25% | 27% | 24% | 24% | 25% | 25% | |
| Net Profit | 18 | 23 | 25 | 29 | 29 | 35 | 34 | 30 | 31 | 30 | 42 | 38 | 44 | |
| EPS in Rs | 3.66 | 4.77 | 4.39 | 5.02 | 5.15 | 6.12 | 5.98 | 5.17 | 5.42 | 5.18 | 7.37 | 6.65 | 7.71 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202650.90%Promoter
Promoters50.90%
FIIs0.85%0.51
DIIs19.16%0.76
Public29.10%0.26
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Innova Captab | ₹1,025.30 | 38.09 | 5,867 | 0.20% | 44 | +42.26% | 471 | +33.94% | 14.96% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports3
Concall transcripts33
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024
Credit ratings6
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Pursuant to regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we are enclosing herewith a copy of the certificate dated 07th ....Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 5 OctShareholder Meeting / Postal Ballot-Scrutinizer''s Report 2 Oct - Innova Captab submitted AGM voting results and scrutinizer report for 30 September 2026 AGM; 10 resolutions passed.Shareholder Meeting / Postal Ballot-Outcome of AGM 30 SepAnnouncement under Regulation 30 (LODR)-Credit Rating 29 Sep - CARE upgraded Innova Captab’s ratings to CARE A+ Stable and CARE A1+ on Rs 459.60 crore facilities.